TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,727,074 | -35.4% | 4,667,458 | +10.9% | 0.00% | -50.0% |
| Q2 2023 | $64,623,852 | -27.9% | 4,207,282 | +5.6% | 0.00% | 0.0% |
| Q1 2023 | $89,613,520 | +21.2% | 3,984,594 | +13.3% | 0.00% | 0.0% |
| Q4 2022 | $73,929,829 | -11.3% | 3,515,446 | +4.0% | 0.00% | 0.0% |
| Q3 2022 | $83,323,000 | +3.2% | 3,381,610 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $80,707,000 | -18.6% | 3,330,819 | -13.4% | 0.00% | 0.0% |
| Q1 2022 | $99,152,000 | -17.7% | 3,847,535 | -0.9% | 0.00% | -33.3% |
| Q4 2021 | $120,462,000 | +28.5% | 3,880,873 | +0.4% | 0.00% | +50.0% |
| Q3 2021 | $93,738,000 | +67.5% | 3,865,481 | +0.8% | 0.00% | +100.0% |
| Q2 2021 | $55,949,000 | -44.0% | 3,834,756 | -4.2% | 0.00% | -66.7% |
| Q1 2021 | $99,920,000 | +7.7% | 4,001,588 | +17.5% | 0.00% | 0.0% |
| Q4 2020 | $92,788,000 | – | 3,404,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |